StockData
ProQR Therapeutics N.V. logo

ProQR Therapeutics N.V. (PRQR) stock

PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 7/30
$1.10−0.05 (-4.35%)

Close on Nov 18, 2026Market cap $115.90MP/E –Yield –

ProQR Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

ProQR Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -€49.01M. For fiscal 2025 it was -€52.79M. The highest annual figure on record is €21.55M in fiscal 2023.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-€52.79M–
FY2024Dec 31, 2024-€36.39M-268.9%
FY2023Dec 31, 2023€21.55M–
FY2022Dec 31, 2022-€68.51M–
FY2021Dec 31, 2021-€26.01M–
FY2020Dec 31, 2020-€47.06M–
FY2019Dec 31, 2019-€43.97M–
FY2018Dec 31, 2018-€28.49M–
FY2017Dec 31, 2017-€34.95M–
FY2016Dec 31, 2016-€34.22M–
FY2015Dec 31, 2015-€24.23M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-€12.27M–
Q1 FY2026Mar 31, 2026-€11.15M–
Q4 FY2025Dec 31, 2025-€13.36M–
Q3 FY2025Sep 30, 2025-€12.24M–
Q2 FY2025Jun 30, 2025-€11.40M–
Q1 FY2025Mar 31, 2025-€15.80M–
Q4 FY2024Dec 31, 2024-€9.35M–
Q3 FY2024Sep 30, 2024-€5.66M–
Q2 FY2024Jun 30, 2024-€6.26M–
Q1 FY2024Mar 31, 2024-€15.13M-133.8%
Q4 FY2023Dec 31, 2023-€5.32M–
Q3 FY2023Sep 30, 2023-€7.51M–
Q2 FY2023Jun 30, 2023-€10.35M–
Q1 FY2023Mar 31, 2023€44.73M–
Q4 FY2022Dec 31, 2022-€17.83M-571.1%
Q3 FY2022Sep 30, 2022-€15.36M–
Q2 FY2022Jun 30, 2022-€14.84M–
Q1 FY2022Mar 31, 2022-€20.47M–
Q4 FY2021Dec 31, 2021€3.79M–
Q3 FY2021Sep 30, 2021-€8.06M–
Q2 FY2021Jun 30, 2021-€9.98M–
Q1 FY2021Mar 31, 2021-€11.76M–
Q4 FY2020Dec 31, 2020-€11.76M–
Q3 FY2020Sep 30, 2020-€9.81M–
Q2 FY2020Jun 30, 2020-€10.49M–
Q1 FY2020Mar 31, 2020-€15.01M–
Q4 FY2019Dec 31, 2019-€11.96M–
Q3 FY2019Sep 30, 2019-€8.77M–
Q2 FY2019Jun 30, 2019-€10.88M–
Q1 FY2019Mar 31, 2019-€12.36M–
Q4 FY2018Dec 31, 2018-€9.10M–
Q3 FY2018Sep 30, 2018-€4.26M–
Q2 FY2018Jun 30, 2018-€5.42M–
Q2 FY2017Jun 30, 2017-€9.85M–

More ProQR Therapeutics figures

See a number that looks wrong?